Endometrial cancer: the individual approach.

[1]  M. Nicoloso,et al.  Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial. , 2023, The Lancet. Oncology.

[2]  J. Ledermann,et al.  Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program , 2022, International Journal of Gynecological Cancer.

[3]  J. Ledermann,et al.  Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Italiano,et al.  Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Tinker,et al.  Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study , 2022, Journal for ImmunoTherapy of Cancer.

[6]  M. Stockler,et al.  Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial , 2021, Journal for ImmunoTherapy of Cancer.

[7]  D. Cella,et al.  Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.